FDA Balks At Renal Cancer Drug From Aveo, Astellas
Aveo Pharmaceuticals Inc. on Monday confirmed that the U.S. Food and Drug Administration has refused to approve kidney cancer medicine tivozanib, a failure that follows the termination of more than half...To view the full article, register now.
Already a subscriber? Click here to view full article